Jan 20 (Reuters) - Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have ...

Why economic leverage beats military pressure on Greenland, and how Denmark’s exposure through Novo Nordisk makes trade tools ...

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.

The Novo Nordisk Foundation has allocated up to 736m euros in funding to BioInnovation Institute (BII), a leading institute ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects healthy upside for Novo Nordisk stock through ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will ...

Roughly 30–50 percent by volume—come from Denmark. That makes the U.S. effectively dependent on Danish production for a ...

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" ...

The iShares MSCI Denmark ETF is rated a buy, supported by Denmark’s strong fundamentals and macroeconomic tailwinds. Learn ...

Florida State University is looking to participate in what could be a groundbreaking drug discovery study through a Denmark-based research consortium.